Immunomedics, Inc. (NASDAQ:IMMU) – Stock analysts at Jefferies Financial Group issued their Q3 2019 earnings per share (EPS) estimates for Immunomedics in a research note issued to investors on Monday, April 8th, according to Zacks Investment Research. Jefferies Financial Group analyst C. Howerton anticipates that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $21.00 price target on the stock. Jefferies Financial Group also issued estimates for Immunomedics’ Q4 2019 earnings at ($0.39) EPS and FY2020 earnings at ($1.26) EPS.
IMMU has been the topic of a number of other research reports. BidaskClub upgraded Immunomedics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Wells Fargo & Co downgraded Immunomedics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $44.00 to $18.00 in a research report on Friday, January 18th. B. Riley set a $28.00 price objective on Immunomedics and gave the stock a “buy” rating in a research report on Wednesday, January 23rd. Berenberg Bank assumed coverage on Immunomedics in a research report on Wednesday, March 27th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Piper Jaffray Companies set a $20.00 price objective on Immunomedics and gave the stock a “buy” rating in a research report on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $28.55.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Monday, February 25th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.16).
Large investors have recently bought and sold shares of the business. Cornerstone Advisors Inc. purchased a new stake in Immunomedics in the first quarter valued at $40,000. Exane Derivatives purchased a new stake in Immunomedics in the fourth quarter valued at $32,000. Karp Capital Management Corp purchased a new stake in Immunomedics in the fourth quarter valued at $33,000. North Star Investment Management Corp. purchased a new stake in Immunomedics in the fourth quarter valued at $50,000. Finally, Pearl River Capital LLC purchased a new stake in Immunomedics in the fourth quarter valued at $66,000. Institutional investors own 85.29% of the company’s stock.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
See Also: Producer Price Index (PPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.